Gram Positive Bacterial Infections Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Global Gram-Positive Bacterial Infections Market Report is Segmented by Drug Type (Beta-Lactam Antimicrobials, Fluoroquinolones, Penicillin, Cephalosporins, RNA Immunoprecipitation (RIP), Vaccine, and Other Drugs), Disease (Pneumonia, Sepsis, Pharyngitis, Methicillin-resistant Staphylococcus aureus (MRSA) Infections, Endocarditis, Meningitis, and Other Diseases), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market size and forecast values are provided in terms of (USD) for all the above segments.

Gram Positive Bacterial Infections Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Gram Positive Bacterial Infections Market Size

Gram-Positive Bacterial Infections Market Summary
Study Period 2021 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
Historical Data Period 2021 - 2023
CAGR 8.00 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Gram-Positive Bacterial Infections Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Gram-positive Bacterial Infections Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Gram Positive Bacterial Infections Market Analysis

The Gram-positive Bacterial Infections Market is expected to register a CAGR of 8% during the forecast period.

The outbreak of COVID-19 had impacted the global healthcare system and significantly impacted the gram-positive bacterial infections market. The increase in COVID-19 cases led to an increase in lung complications such as pneumonia and that surged the demand for drugs against gram-positive bacteria. For instance, an article published by John Hopkins Medicine, in February 2022, reported that pneumonia, caused by COVID-19 filled the lungs with fluid, leading to breathing difficulties. The article also reported an increase in pneumonia cases during the pandemic. Thus, COVID-19 led to an increasing demand for drugs against gram-positive bacteria. However, it was anticipated that with a decrease in COVID-19 cases, the demand for these drugs may get reduced as compared to the initial pandemic times. Still, due to the presence of other gram-positive bacterial infections, the demand for drugs against gram-positive bacteria will keep on increasing. The market is expected to witness significant growth over the forecast period.

The factors that are driving this market are the rising prevalence of gram-positive bacterial infections and an increasing number of drug approvals. For instance, an article published by Merck Manual in September 2022, reported that gram-positive bacteria cause severe infections and in some cases, they may be fatal. The article also said that anthrax is a potentially fatal infection caused by gram-positive bacteria. Thus, the high burden of gram-positive bacterial infections is increasing the demand for drugs to treat them.

Similarly, in May 2022, UNICEF reported that globally, there are over 1,400 cases of pneumonia per 100,000 children, or 1 case per 71 children every year, with the greatest incidence occurring in South Asia (2,500 cases per 100,000 children) and West and Central Africa (1,620 cases per 100,000 children). Thus, such a high incidence of pneumonia (gram-positive bacteria infections) is increasing the demand for drugs against them, thereby driving the growth of the studied market.

Furthermore, to overcome this rising infection caused by gram-positive bacteria, many government authorities like the US FDA and Health Canada, etc are taking initiative and approving many antibiotics to treat this bacterial infection. For instance, in 2021, the US FDA approved 50 new molecules to treat rising bacterial infections. These new molecules were approved by the government to overcome and prevent the spread of rising gram-positive bacterial infections. Thus, the introduction of new molecules that may treat a wide range of gram-positive bacterial infections is expected to drive the growth of the studied market.

Therefore, due to the rising prevalence of gram-positive bacterial infections and increasing number of drug approvals, the market is expected to witness significant growth over the forecast period. However, due to antibiotic resistance, the growth of the studied market may get slow which may affect its growth over the forecast period.

Gram Positive Bacterial Infections Industry Overview

The gram-positive bacterial infections market is competitive and consists of many players operating globally and regionally. However, the large layers of the industry are vertically integrated. Some of the companies which are currently dominating the market are GlaxoSmithKline Plc, Johnson & Johnson Inc., Merck & Co. Inc., Pfizer Inc., AstraZeneca, Cumberland Pharmaceuticals, Novartis AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., Cipla Ltd., Bayer AG, and Bristol-Myers Squibb Company.

Gram Positive Bacterial Infections Market Leaders

  1. Novartis AG

  2. Pfizer

  3. Cipla

  4. Merck & Co. Inc.

  5. GlaxoSmithKline Plc

  6. *Disclaimer: Major Players sorted in no particular order
Gram Positive Bacterial Infection Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Gram Positive Bacterial Infections Market News

  • September 2022: GSK plc and Spero Therapeutics, Inc. received an exclusive license agreement for tebipenem pivoxil hydrobromide (tebipenem HBr), a late-stage antibiotic being developed by Spero, as the oral carbapenem antibiotic to potentially treat complicated urinary tract infections (cUTI), including pyelonephritis, caused by certain bacteria.
  • September 2022: ImprimisRx, America's Ophthalmic Pharmacy, reported the availability of Fortisite, which includes a patent-pending compounded combination of Tobramycin 1.5% and Vancomycin 5%.

Gram Positive Bacterial Infections Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Gram-positive Bacterial Infections
    • 4.2.2 Increasing Number of Drug Approvals
  • 4.3 Market Restraints
    • 4.3.1 Antibiotic Resistance
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Drug Type
    • 5.1.1 Beta-Lactam Antimicrobials
    • 5.1.2 Fluoroquinolones
    • 5.1.3 Penicillin
    • 5.1.4 Cephalosporins
    • 5.1.5 RNA Immunoprecipitation (RIP)
    • 5.1.6 Vaccine
    • 5.1.7 Others Drugs
  • 5.2 By Disease
    • 5.2.1 Pneumonia
    • 5.2.2 Sepsis
    • 5.2.3 Pharyngitis
    • 5.2.4 Methicillin-resistant Staphylococcus aureus (MRSA) Infections
    • 5.2.5 Endocarditis
    • 5.2.6 Meningitis
    • 5.2.7 Other Diseases
  • 5.3 By Distribution Channel
    • 5.3.1 Hospital Pharmacies
    • 5.3.2 Retail Pharmacies
    • 5.3.3 Online Pharmacies
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 GlaxoSmithKline Plc
    • 6.1.2 Johnson & Johnson Inc.
    • 6.1.3 Merck & Co. Inc.
    • 6.1.4 Pfizer Inc.
    • 6.1.5 AstraZeneca
    • 6.1.6 Cumberland Pharmaceuticals
    • 6.1.7 Novartis AG
    • 6.1.8 Sanofi SA
    • 6.1.9 Sun Pharmaceutical Industries Ltd.
    • 6.1.10 Cipla Ltd.
    • 6.1.11 Bayer AG
    • 6.1.12 Bristol-Myers Squibb Company
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Gram Positive Bacterial Infections Industry Segmentation

As per the scope of the report, gram-positive bacteria are among the most common human pathogens associated with clinical infections, which range from mild skin infections to sepsis. Gram-positive bacterial infections include virulence, pathogenesis, immune response, inflammatory response, and drug resistance. several classic gram-positive species cause disease in humans. The most common organisms include Streptococcus, Staphylococcus, Enterococcus, Bacillus, etc. The Gram-Positive Bacterial Infections Market is Segmented by Drug Type (Beta-Lactam Antimicrobials, Fluoroquinolones, Penicillin, Cephalosporins, RNA Immunoprecipitation (RIP), Vaccine, and Other Drugs), Disease (Pneumonia, Sepsis, Pharyngitis, Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, Endocarditis, Meningitis, and Other Diseases), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Drug Type Beta-Lactam Antimicrobials
Fluoroquinolones
Penicillin
Cephalosporins
RNA Immunoprecipitation (RIP)
Vaccine
Others Drugs
By Disease Pneumonia
Sepsis
Pharyngitis
Methicillin-resistant Staphylococcus aureus (MRSA) Infections
Endocarditis
Meningitis
Other Diseases
By Distribution Channel Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Gram Positive Bacterial Infections Market Research FAQs

What is the current Gram-positive Bacterial Infections Market size?

The Gram-positive Bacterial Infections Market is projected to register a CAGR of 8% during the forecast period (2025-2030)

Who are the key players in Gram-positive Bacterial Infections Market?

Novartis AG, Pfizer, Cipla, Merck & Co. Inc. and GlaxoSmithKline Plc are the major companies operating in the Gram-positive Bacterial Infections Market.

Which is the fastest growing region in Gram-positive Bacterial Infections Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Gram-positive Bacterial Infections Market?

In 2025, the North America accounts for the largest market share in Gram-positive Bacterial Infections Market.

What years does this Gram-positive Bacterial Infections Market cover?

The report covers the Gram-positive Bacterial Infections Market historical market size for years: 2021, 2022, 2023 and 2024. The report also forecasts the Gram-positive Bacterial Infections Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Sweden In-Vitro Diagnostics Industry Report

Statistics for the 2025 Gram-positive Bacterial Infections market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Gram-positive Bacterial Infections analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.